盐酸安他唑啉/盐酸四氢唑啉(Antazoline Hydrochloride/Tetryzoline Hydrochloride) - 药物靶点：ADRA1 x H1 receptor_在研适应症：变应性结膜炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Trillerg

靶点

ADRA1 x H1 receptor

作用机制

ADRA1激动剂(肾上腺素能受体α-1家族激动剂)、H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

免疫系统疾病眼部疾病

在研适应症

变应性结膜炎

非在研适应症-

原研机构

Orchidia Pharmaceutical Industries

在研机构

Orchidia Pharmaceutical Industries

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C13H17ClN2

InChIKeyBJORNXNYWNIWEY-UHFFFAOYSA-N

CAS号522-48-5

查看全部结构式(2)

关联

3

项与盐酸安他唑啉/盐酸四氢唑啉相关的临床试验

ChiCTR2000039611

/ Recruiting临床4期IIT

A randomized, controlled clinical study assessing the effectiveness of nifekaline hydrochloride and amiodarone hydrochloride in the maintenance of sinus rhythm after radiofrequency ablation therapy for atrial fibrillation concomitant with valve replacement surgery

开始日期2020-12-01

申办/合作机构-

ChiCTR2000033860

/ Recruiting临床4期IIT

A randomized, controlled clinical study evaluating the effectiveness and safety of nifekaline hydrochloride and amiodarone hydrochloride in the treatment of new-onset atrial fibrillation or atrial flutter after cardiac surgery

开始日期2020-06-01

申办/合作机构-

IRCT201201268827N1

/ CompletedN/AIIT

The effect of cyproheptadin hydrochloride in treatment of mild to moderate failure to thrive in children who referred to clinics of Shiraz University of Medical Sciences at 1390

开始日期2011-11-06

申办/合作机构